Arrivo has a promising pipeline consisting of novel drug candidates addressing patient and physician needs.

  • SP624 represents a completely new approach to treating Depression. Arrivo is at the forefront in the development of this novel Mechanism of Action.  
  • DLX-105 is a completely new way to treat plaque psoriasis with a biologic.  
  • DLX-2323 is an exciting biologic with unique characteristics and a target that has uses across multiple indications.
  • A-767 is a small molecule that has the potential to treat patients with severe acute pancreatitis.  This is a dangerous condition with no good treatment options for patients.